Simulations Plus SLP recently announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders. The company specializes in offering ...

Simulations Plus, Inc. is currently listed on NASDAQ under SLP. One share of SLP stock can currently be purchased for approximately $11.81. Is Simulations Plus, Inc. (SLP) overvalued or undervalued?

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Image source: The Motley Fool. Need a quote from one of our analysts? Email [email protected] Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. A $77.2 ...

Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...

The fiscal 2025 preliminary results and fiscal 2026 guidance set forth above are preliminary and unaudited based on currently available information and management estimates and are subject to ...

Simulations Plus, Inc.SLP was a big mover last session, as the company saw its shares rise nearly 6% on the day. Shares gained after the company reported higher earnings and revenues for the third ...

Simulations Plus SLP reported third-quarter fiscal 2021 earnings of 18 cents per share, up 13% on a year-over-year basis. The figure beat the Zacks Consensus Estimate by 5.9%. Revenues of $12.8 ...

Simulations Plus, founded in 1996, has established itself as a key player in the bio-simulation market, second only to its larger competitor, Certara (NASDAQ:CERT). The company's business model is ...

Polen Capital Management, a value-driven, concentrated, long-term investment management firm, published its ‘Polen U.S. Small Company Growth’ fourth-quarter 2020 Investor Letter – a copy of which can ...